Trial Profile
A Phase II Study of Avelumab in Subjects With Recurrent Respiratory Papillomatosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Therapeutic Use
- 01 Nov 2021 Status changed from active, no longer recruiting to completed.
- 27 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Aug 2016 New trial record